KU-19-19Homo sapiens (Human)Cancer cell line

Also known as: Keio University-19-19, KU1919, KU19-19, KU 19-19

🤖 AI SummaryBased on 11 publications

Quick Overview

Bladder cancer cell line with AKT1 mutations and cytokine production.

Detailed Summary

The KU-19-19 cell line is a human bladder cancer cell line derived from a 76-year-old male patient with metastatic transitional cell carcinoma. It is known for its ability to produce multiple cytokines, including granulocyte colony-stimulating factor (G-CSF), granulocyte-macrophage colony-stimulating factor (GM-CSF), macrophage colony-stimulating factor (M-CSF), stem cell factor (SCF), interleukin-6 (IL-6), and interleukin-8 (IL-8). This cell line exhibits constitutive activation of the AKT1 pathway due to the presence of the E17K mutation, which contributes to its proliferative and survival advantages. KU-19-19 has been used in studies investigating the role of cytokines in cancer progression and the effects of various treatments on cytokine production and cell proliferation. It is also utilized in research on the regulation of the NF-κB pathway and its impact on cell survival and cytokine expression.

Research Applications

AKT1 mutation analysisCytokine production studiesNF-κB pathway regulationDrug sensitivity testingTumor biology investigation

Key Characteristics

AKT1 E17K mutationConstitutive AKT1 activationCytokine secretion (G-CSF, GM-CSF, M-CSF, SCF, IL-6, IL-8)Autocrine growth via G-CSFNF-κB activation

Generated on 6/16/2025

Basic Information

Database ID	CVCL_1344
Species	Homo sapiens (Human)
Tissue Source	Urinary bladder[UBERON:UBERON_0001255]

Donor Information

Age	76
Age Category	Adult
Sex	Female

Disease Information

Disease	Bladder carcinoma
Lineage	Bladder/Urinary Tract
Subtype	Bladder Urothelial Carcinoma
OncoTree Code	BLCA

DepMap Information

Source Type	DSMZ
Source ID	ACH-000486_source

Known Sequence Variations

Type	Gene/Protein	Description	Zygosity	Note	Source
MutationSimple	AKT1	p.Glu17Lys (c.49G>A)	Heterozygous	-	from parent cell line IHH-4

Haplotype Information (STR Profile)

Short Tandem Repeat (STR) profile for cell line authentication.

Amelogenin

CSF1PO

9,10

D13S317

D16S539

10,12

D18S51

17,20

D19S433

13,15

D21S11

30,32

D2S1338

D3S1358

16,17

D5S818

11,12

D7S820

10,12

D8S1179

10,13

FGA

Penta D

Penta E

10,15

TH01

7,8

TPOX

8,11

vWA

14,15

Gene Expression Profile

Gene expression levels and statistical distribution

Loading cohorts...

Full DepMap dataset with combined data across cell lines

Loading gene expression data...

Publications

Pan-cancer proteomic map of 949 human cell lines.";

Robinson P.J., Zhong Q., Garnett M.J., Reddel R.R.

Cancer Cell 40:835-849.e8(2022).

DOI PubMed PMC

Quantitative proteomics of the Cancer Cell Line Encyclopedia.";

Sellers W.R., Gygi S.P.

Cell 180:387-402.e16(2020).

DOI PubMed PMC

Next-generation characterization of the Cancer Cell Line Encyclopedia.

Sellers W.R.

Nature 569:503-508(2019).

DOI PubMed PMC

An interactive resource to probe genetic diversity and estimated ancestry in cancer cell lines.

Dutil J., Chen Z.-H., Monteiro A.N.A., Teer J.K., Eschrich S.A.

Cancer Res. 79:1263-1273(2019).

DOI PubMed PMC

Systematic review: characteristics and preclinical uses of bladder cancer cell lines.

Zuiverloon T.C.M., de Jong F.C., Costello J.C., Theodorescu D.

Bladder Cancer 4:169-183(2018).

DOI PubMed PMC

A landscape of pharmacogenomic interactions in cancer.";

Wessels L.F.A., Saez-Rodriguez J., McDermott U., Garnett M.J.

Cell 166:740-754(2016).

DOI PubMed PMC

TCLP: an online cancer cell line catalogue integrating HLA type, predicted neo-epitopes, virus and gene expression.

Loewer M., Sahin U., Castle J.C.

Genome Med. 7:118.1-118.7(2015).

DOI PubMed PMC

Identification of mutations in distinct regions of p85 alpha in urothelial cancer.

Knowles M.A.

PLoS ONE 8:E84411-E84411(2013).

DOI PubMed PMC

Comprehensive mutation analysis of the TERT promoter in bladder cancer and detection of mutations in voided urine.

Hurst C.D., Platt F.M., Knowles M.A.

Eur. Urol. 65:367-369(2014).

DOI PubMed

The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity.

Morrissey M.P., Sellers W.R., Schlegel R., Garraway L.A.

Nature 483:603-607(2012).

DOI PubMed PMC

Signatures of mutation and selection in the cancer genome.";

Deloukas P., Yang F.-T., Campbell P.J., Futreal P.A., Stratton M.R.

Nature 463:893-898(2010).

DOI PubMed PMC

AKT1 mutations in bladder cancer: identification of a novel oncogenic mutation that can co-operate with E17K.

Knowles M.A.

Oncogene 29:150-155(2010).

DOI PubMed

Overexpression of IL-1ra gene up-regulates interleukin-1beta converting enzyme (ICE) gene expression: possible mechanism underlying IL-1beta-resistance of cancer cells.

Takayanagi A., Shimizu N.

Br. J. Cancer 81:277-286(1999).

DOI PubMed PMC

Induction of apoptosis of cytokine-producing bladder cancer cells by adenovirus-mediated IkappaBalpha overexpression.

Nakamura H., Takayanagi A., Shimizu N.

Hum. Gene Ther. 10:37-47(1999).

DOI PubMed

Bladder carcinoma cell line KU-19-19-derived cytokines support proliferation of growth factor-dependent hematopoietic cell lines: modulation by phorbol ester, interferon-gamma and interleukin-1 beta.

Steube K.G., Meyer C., Tachibana M., Murai M., Drexler H.G.

Biochem. Biophys. Res. Commun. 242:497-501(1998).

DOI PubMed

Autocrine growth of transitional cell carcinoma of the bladder induced by granulocyte-colony stimulating factor.

Nishi T., Amano Y.

Cancer Res. 55:3438-3443(1995).

PubMed

Web Resources

cells-talk.com